Lymphoma (includes NHL, HL, CNS Lymphoma)

Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients

(NASDAQ) July 18, 2018 - Cellectar Biosciences, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces positive interim results from the company's Phase 2 clinical trial for its lead product candidate CLR 131, in patients with diffuse large B-cell lymphoma (DLBCL).

read article

Staggering Prices Slow Insurers’ Coverage Of CAR-T Cancer Therapy

(Kaiser Health News) July 17, 2018 - Patients whose blood cancers have failed to respond to repeated rounds of chemotherapy may be candidates for a new type of gene therapy that could send their cancers into remission for years.

read article

AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program

(StreetInsider) July 11, 2018 - AbbVie, a research-based global biopharmaceutical company, today announced an update on a Phase 3 study (DBL3001) of ibrutinib (IMBRUVICA®) in untreated (treatment-naïve) diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma (NHL).

read article

Nanoparticles Give Immune Cells A Boost

(MIT News) July 9, 2018 - Programming the body’s immune system to attack cancer cells has had promising results for treating blood cancers such as lymphoma and leukemia.

read article

Results of Phase III (PIX306) Study Evaluating Progression-Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma

(CTI BioPharma) July 9, 2018 - CTI BioPharma Corp. and Servier today announced that the pivotal Phase III trial (PIX306) evaluating PIXUVRI® (pixantrone) combined with rituximab in comparison to gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin lymphoma (NHL) did not meet its primary endpoint of an improvement in progression-free survival (PFS).

read corporate press release

CTI Biopharma's Cancer Drug Fails Late-Stage Trial, Shares Tumble

(Reuters) July 9, 2018 - CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the main goal of a late-stage trial, sending its shares down 17 percent.

read article

Meeting Highlights From The Committee For Medicinal Products For Human Use (CHMP) 25-28 June 2018

(EMA) June 29, 2018 - The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended nine medicines for approval, including six orphan medicines1, at its June 2018 meeting.

read press release

Novartis Receives Positive CHMP Opinion For Kymriah® For Treating Two Aggressive Blood Cancers, Marking Important Medical Advance For Patients In Europe

(Novartis) June 29, 2018 - Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of Kymriah® (tisagenlecleucel, formerly CTL019) - a novel one-time treatment that uses a patient's own T cells to fight cancer.

read corporate press release

European CHMP Adopts Positive Opinion for Yescarta® (axicabtagene ciloleucel) for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy

(StreetInsider) June 29, 2018 - Kite, a Gilead Company, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company’s Marketing Authorization Application (MAA) for Yescarta® (axicabtagene ciloleucel) as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.

read article

Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial

(Cellectar) June 28, 2018 - Cellectar Biosciences, Inc. today announces that the company will expand patient enrollment in the diffuse large b-cell lymphoma (DLBCL) cohort of its currently enrolling Phase 2 clinical trial of CLR 131.

read corporate press release

FDA to Release List of Surrogate Endpoints in Oncology

(Regulatory Focus) June 25, 2018 - Scott Gottlieb, FDA Commissioner, said Monday at the National Press Club in Washington, DC that his agency will release a list of surrogate endpoints used in cancer drug development soon.

read article

Is Chemo Obsolete? Not By A Long Shot, Cancer Experts Say

(NBC News) June 24, 2018 - New cancer treatments usually only help a fraction of cancer patients.

read article

IMBRUVICA® (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer

(AbbVie) June 25, 2018 - The filing is based on data from the Phase 3 iNNOVATE study, which suggest that IMBRUVICA plus rituximab may improve outcomes across all lines of Waldenström's macroglobulinemia (WM) treatment, including patients with prior lines of therapy and various genetic factors, versus rituximab alone; if approved, the sNDA would expand the FDA's prescribing information for IMBRUVICA in WM as the first chemotherapy-free combination treatment option.

read corporate press release

Trial Begins For Man Alleging Roundup Weed Killer Caused His Cancer

(ABC News) June 18, 2018 - A California man is the first of hundreds of plaintiffs to see his day in court with Monsanto in a lawsuit alleging that its weed killing product Roundup gave him cancer.

read article

Novartis JULIET Trial Of Kymriah Demonstrates More Than One-year Durability Of Responses In Adults With Relapsed Or Refractory DLBCL

(Novartis) June 16, 2018 - Novartis today announced 14-month results from the pivotal JULIET clinical trial showing ongoing durable responses are achievable with Kymriah® (tisagenlecleucel) when administered to adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

read corporate press release

Verastem Oncology Presents Duvelisib Data at EHA 2018 Annual Meeting

(Verastem) June 16, 2018 - Phase Ib/II study of duvelisib in combination with FCR (dFCR) achieves ORR of 94% and 76% bone marrow MRD negativity in frontline therapy in younger CLL patients; duvelisib demonstrates robust clinical activity in CLL with 73% ORR and a median of 15 month PFS in the DUO crossover study of patients who became relapsed/refractory to ofatumumab in DUO™.

read corporate press release

Ziopharm Oncology Shares Slide 7% Premarket After FDA Places Clinical Hold On Cancer Trial

(MarketWatch) June 18, 2018 - Ziopharm Oncology Inc. said Monday the U.S. Food and Drug Administration has placed a clinical hold on a Phase 1 trial of a treatment for cancer.

read article

Continued Discussions With FDA On Proposed Remetinostat Phase III Design Results In Delay In Planned Start Of Study

(Medivir) June 18, 2018 - Medivir AB today announced that the Board of Directors have decided to continue the discussions with the US Food and Drug Administration (FDA) to agree on the design of the planned pivotal phase III clinical study of remetinostat for the treatment of early-stage cutaneous T-cell lymphoma (CTCL).

read corporate press release

Epizyme Reports Positive Updated Interim Data from Phase 2 Study of Tazemetostat in Patients With Relapsed or Refractory Follicular Lymphoma at the Congress of the European Hematology Association (EHA)

(NASDAQ) June 15, 2018 - Consistently high responses in patients with an EZH2 activating mutation; durable clinical responses and progression-free survival observed in patients with or without an EZH2 activating mutation.

read article

JAK Inhibitors Associated with Aggressive Lymphoma

(ASH) June 15, 2018 - Austrian researchers have discovered that a small number of patients taking targeted drugs known as Janus kinase (JAK) inhibitors to treat myelofibrosis may develop aggressive lymphomas.

read press release
Next Page